Asgard Therapeutics appoints Dr Wolfram Brugger as CMO 

Biotechnology company Asgard Therapeutics has appointed Dr Wolfram Brugger as Chief Medical Officer. 

Brugger, who has been involved in more than 130 Phase I to III clinical oncology trials across a wide variety of cancer types, has been appointed to strengthen Asgard’s leadership as it prepares to transition to a clinical-stage biotech. 

Brugger joins Asgard from Autolus Therapeutics, where he led the global clinical development programme of an autologous CD19 CAR–T therapy in haematological and autoimmune indications.  

Prior to that, Brugger headed the global clinical development programme at MorphoSys and, at AstraZeneca, he was Global Medical Lead for Phase I/early Phase II trials for several oncology assets in numerous cancer types. 

“I’ve always been driven by bringing new modalities to patients, and I am excited to be developing a ‘personalised off-the-shelf’ immunotherapy which has great potential to help patients with a wide variety of cancers,” Brugger said. 

“Asgard’s in vivo cell reprogramming technology has transformative potential, and the pre-clinical proof-of-concept data, both published and upcoming data to be presented at key scientific conferences, is highly convincing.  

“Having treated hundreds of cancer patients in clinical trials throughout my career, I look forward to utilising my experience to shape Asgard’s clinical strategy, driving AT-108 through clinical development.” 

“Strengthening our leadership team with Wolfram, who is such a highly experienced clinical trials expert and practicing medical oncologist, is a privilege and we are excited to welcome him on board,” added Cristiana Pires, Co-founder and Chief Executive Officer of Asgard Therapeutics. 

“Wolfram’s proven capabilities and track record will ensure that Asgard is perfectly positioned as we advance AT-108 towards the clinic.” 

The post Asgard Therapeutics appoints Dr Wolfram Brugger as CMO  appeared first on Drug Discovery World (DDW).